- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00531271
ABI-008 Trial in Patients With Metastatic Breast Cancer
A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Metastatic Breast Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas M.D. Anderson Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Phase I Study
Each subject must meet the following criteria to be enrolled in this study.
- Pathologically confirmed adenocarcinoma of the breast with metastasis.
- No more than 2 prior chemotherapy regimen for metastatic breast cancer. Patient should have received anthracycline and may have received a taxane but not within 6 months for registration on the study.
- Patient may have measurable or evaluable disease.
- Patient may have non-measurable bone only disease.
- At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
- At least 4 weeks since radiotherapy, with full recovery.
- At least 4 weeks since recovery from major surgery, with full recovery.
- ECOG performance status 0-2.
- Age ≥18 years.
Patient must have the following blood counts at Baseline:
- WBC > 3.0 x 109 cells/L;
- ANC ≥ 1.5 x 109 cells/L;
- Platelets ≥ 100 x 109 cells/L;
- Hgb ≥ 9 grams/dL.
Patient has the following blood chemistry levels at Baseline:
- AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
- Total Bilirubin < ULN;
- Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
- Creatinine ≤ 1.5 mg/dL.
- Peripheral neuropathy Grade 0 or stable Grade 1, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0.
- If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
- If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
- Life expectancy should be ≥ 3 months.
- Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.
- If obese, a patient must be treated with doses calculated using his/her actual body surface area (BSA) (the physician must be comfortable treating at the full BSA dose regardless of BSA).
Phase II Study
- Pathologically confirmed adenocarcinoma of the breast with metastasis.
- Patients should have not received prior chemotherapy for their metastatic disease. If a taxane is used as adjuvant or neoadjuvant therapy, at least 12 months should have elapsed from the date of the last dose.
- Patient must have at least one measurable metastatic lesion.
- At least 4 weeks since prior cytotoxic chemotherapy. Patients should have recovered from all acute effects of such therapy.
- At least 4 weeks since radiotherapy, with full recovery.
- At least 4 weeks since major surgery, with full recovery.
- ECOG performance status 0-2.
- Age ≥18 years.
Patient must have the following blood counts at Baseline:
- WBC > 3.0 x 109 cells/L;
- ANC ≥ 1.5 x 109 cells/L;
- Platelets ≥ 100 x 109 cells/L;
- Hgb ≥ 9 grams/dL.
Patient has the following blood chemistry levels at Baseline:
- AST (SGOT), ALT (SGPT) ≤ 1.5x upper limit of normal range (ULN);
- Total Bilirubin < ULN;
- Alkaline phosphatase ≤ 2.5x ULN (unless bone metastasis is present in the absence of liver metastasis);
- Creatinine ≤ 1.5 mg/dL.
- Peripheral neuropathy Grade 0 or stable Grade 1, by NCI CTCAE v3.0.
- If female of childbearing potential, serum pregnancy test is negative (within 72 hours of the first dose of study drug).
- If fertile, the patient agrees to use an effective method to avoid pregnancy for the duration of the study.
- Life expectancy should be ≥ 3 months.
- Informed consent document has been obtained stating that the patient understands the investigational nature of the proposed treatment.
Exclusion Criteria:
Phase I Study
Subjects who meet any of the following criteria will be excluded from the study.
- Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer. Bisphosphonates are allowed.
- Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
- History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
- Patients who have received an investigational drug within the previous 4 weeks.
- Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered. A patient may not enroll in such clinical trials while participating in this study.
- Pregnant or nursing women.
- Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
- ECOG performance status 3-4.
- Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel. Appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated.
Phase II Study
Subjects who meet any of the following criteria will be excluded from the study.
- Prior neo-adjuvant or adjuvant chemotherapy is allowed. If a taxane was part of the adjuvant regimen, at least 12 months should have transpired since completion of taxane regimen.
- Concurrent therapy (chemotherapy, hormonal therapy, kinase inhibitors, immunotherapy, etc) for breast cancer.
- Parenchymal brain metastases, unless documented to be clinically and radiographically stable for at least 6 months after treatment.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association Class III or IV), active angina pectoris or recent myocardial infarction (within the last 6 months).
- History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer excluding non-melanomatous skin cancer and cervical carcinoma in situ.
- Patients who have received an investigational drug within the previous 4weeks.
- Patient is currently enrolled in any other clinical study in which investigational procedures are performed or investigational therapies are administered.
- Pregnant or nursing women.
- Patients with history of allergic reactions attributed to solvent-based docetaxel(Taxotere).
- ECOG performance status 3-4.
- Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy, HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with docetaxel.
- Patients with tumor overexpression of HER2/neu.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every three weeks.
Tijdsspanne: End of Study (EOS) and Follow Up
|
End of Study (EOS) and Follow Up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To evaluate the safety and tolerability of ABI-008 in the metastatic breast cancer patient population; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule.
Tijdsspanne: End of Study (EOS) and Follow Up
|
End of Study (EOS) and Follow Up
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nuhad Ibrahim, MD, M.D. Anderson Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CA302
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Uitgezaaide borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op ABI-008 (nab-docetaxel)
-
CelgeneVoltooidHormoon refractaire prostaatkankerVerenigde Staten
-
CelgeneVoltooidColorectale neoplasmataFrankrijk
-
CelgeneVoltooid
-
Aadi Bioscience, Inc.VoltooidKwaadaardige PEComaVerenigde Staten
-
Aadi Bioscience, Inc.Goedgekeurd voor marketingTSC1 | TSC2 | PEComa, kwaadaardig | mTOR Pathway-afwijking
-
CelgeneVoltooid
-
CelgeneVoltooidVaste tumorenVerenigde Staten
-
Aadi Bioscience, Inc.WervingKwaadaardig solide neoplasma | Neoplasmata | Kanker | Neoplasma metastase | Vaste tumor | Uitgezaaide kanker | Metastase | Geavanceerde vaste tumor | Metastatische vaste tumor | Geavanceerde kanker | Tumor | Kwaadaardig neoplasma | Kwaadaardige tumor | Tumoren | Kanker uitgezaaid | Tumor, solide | Kwaadaardige vaste tumor | TSC en andere voorwaardenKorea, republiek van, Verenigde Staten, Puerto Rico
-
Aadi Bioscience, Inc.National Cancer Institute (NCI)VoltooidNiet-spierinvasieve blaaskanker (NMIBC)Verenigde Staten
-
Aadi Bioscience, Inc.WervingKanker | Endometriumkanker | Tumor | Recidiverend endometriumcarcinoom | Endometrioïde endometriumkanker | Endometrioïde tumorVerenigde Staten